Epigenetic Regulation of Anti-tumor Immune Response
A special issue of Epigenomes (ISSN 2075-4655).
Deadline for manuscript submissions: closed (31 January 2019) | Viewed by 250
Special Issue Editor
Special Issue Information
Dear Colleagues,
Evasion from immunosurveillance by cancer cells is a major cancer hallmark, and restoration of immunosurveillance has been demonstrated as an effective anti-tumor strategy. For example, immune checkpoint inhibitors have achieved remarkable responses. Recent studies showed that epigenetic aberrations contribute to downregulation of anti-tumor immune responses. Epigenetic targeting has shown promising effects by inducing robust anti-tumor immune response, alone or in combination with immune checkpoint inhibitors. This Special Issue is focused on the study of epigenetic regulators of anti-tumor immune response, as well as epigenetic-based therapeutics for cancer treatment. We will consider review, research, or method manuscripts with a broad interest in these areas.
Dr. Qin Yan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Cancer epigenetics
- Anti-tumor Immune response
- Immune checkpoint blockade
- Tumor immunology
- Immunotherapy
